Metabolic consequences of treating hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Syndrome

Background:

• Hypertension management aims to reduce morbidity and mortality.
• Antihypertensive drug trials have shown success in preventing stroke, congestive heart failure (CHF), and renal disease.
• However, reducing coronary heart disease (CHD) endpoints has been less successful.

Purpose of the Study:

• To evaluate the impact of antihypertensive therapies on cardiovascular and renal outcomes.
• To investigate the role of metabolic side effects of certain antihypertensive drugs on their efficacy in preventing CHD.
• To highlight newer drug classes that avoid these metabolic disturbances.

Main Methods:

• Review of major antihypertensive drug trials and their outcomes.
• Analysis of the metabolic effects (lipid and carbohydrate metabolism, insulin resistance) of different antihypertensive drug classes.
• Comparison of efficacy in preventing stroke, CHF, renal disease, and CHD.

Main Results:

• Diuretics and beta-blockers, while effective for blood pressure reduction, are associated with adverse effects on lipid and carbohydrate metabolism.
• These metabolic changes may explain the limited success in reducing CHD endpoints with these older drug classes.
• Calcium antagonists, ACE inhibitors, and alpha 1-antagonists do not share these adverse metabolic effects and offer an alternative approach.

Conclusions:

• Effective hypertension management requires not only blood pressure reduction but also addressing accompanying metabolic abnormalities.
• The choice of antihypertensive medication should consider potential metabolic side effects, particularly concerning CHD risk.
• Emerging evidence supports the use of newer drug classes with favorable metabolic profiles for comprehensive hypertension management.